Orion Pharma (DHA:ORIONPHARM) Cyclically Adjusted FCF per Share: BDT-0.87 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
72 GF Score
Price BDT30.10
GF Value BDT20.17
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Cyclically Adjusted FCF per Share?

Orion Pharma DHA:ORIONPHARM -2.27% 72 Cyclically Adjusted FCF per Share is BDT-0.87 as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.17 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Orion Pharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was BDT-0.189. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is BDT-0.87 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Orion Pharma's average Cyclically Adjusted FCF Growth Rate was -341.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-14), Orion Pharma's current stock price is BDT30.10. Orion Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was BDT-0.87. Orion Pharma's Cyclically Adjusted Price-to-FCF of today is .

During the past 12 years, the highest Cyclically Adjusted Price-to-FCF of Orion Pharma was 736.00. The lowest was 26.38. And the median was 49.13.


Orion Pharma  (DHA:ORIONPHARM) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 12 years, the highest Cyclically Adjusted Price-to-FCF of Orion Pharma was 736.00. The lowest was 26.38. And the median was 49.13.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Orion Pharma Cyclically Adjusted FCF per Share Related Terms


Orion Pharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Cyclically Adjusted FCF per Share Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.98 1.27 0.68

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.68 0.05 -0.74 -0.87

DHA:ORIONPHARM vs CEG, VST, NRG: Cyclically Adjusted FCF per Share Comparison

For the Utilities - Independent Power Producers subindustry, Orion Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Pharma Cyclically Adjusted Price-to-FCF vs Utilities - Independent Power Producers Industry

For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Orion Pharma's Cyclically Adjusted Price-to-FCF falls into.


DHA:ORIONPHARM
72GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orion Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.189/330.2130*330.2130
=-0.189

Current CPI (Mar. 2026) = 330.2130.

Orion Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201509 0.929 237.945 1.289
201609 0.872 241.428 1.193
201612 1.055 241.432 1.443
201703 4.854 243.801 6.574
201706 -1.124 244.955 -1.515
201709 2.243 246.819 3.001
201712 1.144 246.524 1.532
201803 2.518 249.554 3.332
201806 -0.792 251.989 -1.038
201809 1.338 252.439 1.750
201812 1.347 251.233 1.770
201903 2.407 254.202 3.127
201906 -3.706 256.143 -4.778
201909 0.752 256.759 0.967
201912 -1.087 256.974 -1.397
202003 -1.694 258.115 -2.167
202006 2.328 257.797 2.982
202009 0.145 260.280 0.184
202012 -5.369 260.474 -6.806
202103 1.726 264.877 2.152
202106 -3.704 271.696 -4.502
202109 -3.631 274.310 -4.371
202112 -1.469 278.802 -1.740
202203 -4.594 287.504 -5.276
202206 3.262 296.311 3.635
202209 -0.871 296.808 -0.969
202212 1.915 296.797 2.131
202303 -6.682 301.836 -7.310
202306 -0.201 305.109 -0.218
202309 -0.202 307.789 -0.217
202312 -2.886 306.746 -3.107
202403 -1.930 312.332 -2.040
202406 3.472 314.175 3.649
202409 -1.814 315.301 -1.900
202412 -0.360 315.605 -0.377
202503 -1.399 319.799 -1.445
202506 5.013 322.561 5.132
202509 0.099 324.800 0.101
202512 -3.210 324.054 -3.271
202603 -0.189 330.213 -0.189

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of BDT-0.87 mean?
Orion Pharma (DHA:ORIONPHARM) has a Cyclically Adjusted FCF per Share of BDT-0.87 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Orion Pharma and its competitors.
Is Orion Pharma's Cyclically Adjusted FCF per Share too high?
Orion Pharma's current Cyclically Adjusted FCF per Share is BDT-0.87. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Cyclically Adjusted FCF per Share compare to CEG and VST?
Orion Pharma's Cyclically Adjusted FCF per Share of BDT-0.87 can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for an Utilities - Independent Power Producers company?
A good Cyclically Adjusted FCF per Share depends on the Utilities - Independent Power Producers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Orion Pharma and its competitors. Orion Pharma's current Cyclically Adjusted FCF per Share is BDT-0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.17, compared to a current price of BDT30.10 — trading 49.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is BDT-0.87. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Cyclically Adjusted FCF per Share is BDT-0.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT30.10 is trading 49.2% above its estimated GF Value™ of BDT20.17. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Cyclically Adjusted FCF per Share: BDT-0.87
  • GF Value™: BDT20.17 vs. price of BDT30.10 (49.2% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score

Get the complete analysis for DHA:ORIONPHARM

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT30.10
Price
BDT20.17
GF Value